FrancophonIA/ELRC3.0 huggingface dataset:
English: There is an increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition, or hepatic impairment) due to the metformin active substance of Vokanamet (see section 4.4).
Croatian: Postoji povećan rizik za laktacidozu tijekom akutne alkoholne intoksikacije (naročito u slučaju gladovanja, pothranjenosti ili oštećenja jetrene funkcije) radi metformina, djelatne tvari u lijeku Vokanamet (vidjeti dio 4.4).
English: ● and delay of intestinal glucose absorption.
Croatian: ● odgađajući intestinalnu apsorpciju glukoze.
English: As metformin is excreted by the kidney, and metformin accumulation may precipitate lactic acidosis, eGFR or creatinine clearance should be determined before initiating treatment and regularly thereafter:
Croatian: Budući da se metformin izlučuje putem bubrega, i da nakupljanje metformina može precipitirati laktacidozu, prije početka liječenja i redovito nakon toga moraju se odrediti eGFR ili klirens kreatinina:
English: The safety and efficacy of canagliflozin in patients with type 1 diabetes have not been established and Vokanamet should not be used for treatment of patients with type 1 diabetes.
Croatian: Sigurnost i djelotvornost kanagliflozina u bolesnika sa šećernom bolešću tipa 1 nisu ustanovljene te se kanagliflozin ne smije primjenjivati u liječenju bolesnika sa šećernom bolešću tipa
English: Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/L, and an increased anion gap and lactate/pyruvate ratio.
Croatian: Dijagnostički laboratorijski nalazi su snižen pH krvi, razina laktata u krvi iznad 5 mmol/L i povišen anionski rascjep,
English: Table 5: Efficacy results from active-controlled clinical studiesa
Croatian: Tablica 5: Rezultati djelotvornosti iz aktivno-kontroliranih ispitivanjaa
English: Vokanamet is not recommended in patients with hepatic impairment due to the active substance metformin (see sections 4.3 and 5.2).
Croatian: Vokanamet se ne preporučuje u bolesnika s oštećenjem jetrene funkcije zbog djelatne tvari metformina (vidjeti dijelove 4.3 i 5.2).
English: Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people) These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions): increased levels of “ketone bodies” in your urine or blood rapid weight loss feeling sick or being sick stomach pain excessive thirst fast and deep breathing confusion unusual sleepiness or tiredness a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
Croatian: Ovo su znakovi dijabetičke ketoacidoze (također vidjeti dio 2 Upozorenja i mjere opreza): povišene razine “ketonskih tijela” u mokraći ili krvi nagli gubitak tjelesne težine mučnina ili povraćanje bol u trbuhu prekomjerna žeđ ubrzano i duboko disanje smetenost neuobičajena pospanost ili umor zadah slatkog mirisa, slatki ili metalni okus u ustima ili drugačiji miris mokraće ili znoja.
English: Canagliflozin + metformin
Croatian: Kanagliflozin + metformin
English: • very common: feeling sick (nausea), being sick (vomiting), diarrhoea, stomach ache, and loss of appetite
Croatian: ● vrlo često: mučnina, povraćanje, proljev, bol u trbuhu i gubitak teka
English: In general, canagliflozin produced clinically and statistically significant (p < 0.001) results relative to placebo in glycaemic control, including glycosylated haemoglobin (HbA1c), the percentage of patients achieving HbA1c < 7%, change from baseline fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG).
Croatian: Općenito, kanagliflozin je imao klinički i statistički značajne (p<0,001) rezultate u odnosu na placebo u regulaciji glikemije, uključujući HbA1c, postotak bolesnika koji su postigli glikozilirani hemoglobin (HbA1c),< 7%, promjenu u odnosu na početnu vrijednost glukoze u plazmi natašte (FPG) i 2-satne postprandijalne glukoze (PPG).
English: d p < 0.001.
Croatian: c Nije primjenjivo. d p<0,001.
English: Statistically significant (p < 0.001) changes from baseline HbA1c relative to placebo of -0.57% and -0.70% were observed for 100 mg once daily and 300 mg once daily, respectively (see sections 4.2 and 4.8).
Croatian: Statistički značajne (p<0,001) promjene početne vrijednosti HbA1c u odnosu na placebo od -0,57% i -0,70% uočene su uz 100 mg jedanput na dan odnosno 300 mg jedanput na dan (vidjeti dijelove 4.2 i 4.8).
English: • in patients already being treated with the combination of canagliflozin and metformin as separate tablets.
Croatian: ● u bolesnika koji se već liječe kombinacijom kanagliflozina i metformina u pojedinačnim tabletama.
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati Vokanamet Ovaj lijek čuvajte izvan pogleda i dohvata djece.
English: Studies characterising the pharmacokinetics of canagliflozin in paediatric patients have not been conducted.
Croatian: Nisu provedena ispitivanja farmakokinetike kanagliflozina u pedijatrijskih bolesnika.
English: For patients with an estimated glomerular filtration rate (eGFR) 60 mL/min/1.73 m2 to < 90 mL/min/1.73m2 or creatinine clearance (CrCl) of 60 mL/min to < 90 mL/min, no dose adjustment is needed.
Croatian: U bolesnika s procijenjenom brzinom glomerularne filtracije (eGFR) 60 mL/min/1,73 m2 do < 90 mL/min/1,73 m2 ili s klirensom kreatinina (CrCl) od 60 mL/min do < 90 mL/min, nije potrebna prilagodba doze.
English: In a pooled analysis of clinical data, increases in canagliflozin AUC of 26% were observed in UGT1A9*1/*3 carriers and 18% in
Croatian: bila su uočena povišenja AUC-a kanagliflozina od 26% u UGT1A9*1/*3 nositelja i 18% u
English: • if you have recently had a heart attack or have severe blood circulation problems, such as
Croatian: ● ako ste nedavno imali srčani udar ili imate teške probleme s cirkulacijom krvi, poput ‘šoka“ ili poteškoća s disanjem
English: • very rare: decreased vitamin B12 levels (may cause anaemia - low count of red blood cells),
Croatian: ● vrlo rijetko: smanjene razine vitamina B12, (može izazvati anemiju - nizak broj crvenih krvnih stanica), poremećaji pretraga jetrene funkcije, hepatitis (problem s jetrom) i svrbež.
English: Before initiating Vokanamet, factors in the patient history that may predispose to ketoacidosis should be considered.
Croatian: Prije početka liječenja kanagliflozinom, potrebno je u anamnezi bolesnika razmotriti moguće predisponirajuće faktore za ketoacidozu.
English: g Vulvovaginal candidiasis includes the terms vulvovaginal candidiasis, vulvovaginal mycotic infection, vulvovaginitis,
Croatian: g Vulvovaginalna kandidijaza uključuje termine vulvovaginalna kandidijaza, vulvovaginalna gljivična infekcija,
English: Balanitis or balanoposthitis includes the terms balanitis, balanoposthitis, balanitis candida, and genital infection fungal.
Croatian: h Balanitis ili balanopostitis uključuju termine balanitis, balanopostitis, balanitis uzrokovan kandidom i genitalna gljivična infekcija.
English: • Diabetic ketoacidosis, diabetic pre-coma;
Croatian: Dijabetička ketoacidoza, dijabetička prekoma;
English: Glimepiride (titrated) + metformin (N=482)
Croatian: Glimepirid (titrirani) + metformin (N=482)
English: Placebo + insulin (N = 565)
Croatian: Placebo + inzulin (N=565)
English: Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs.
Croatian: Farmakoterapijska skupina: Lijekovi za liječenje šećerne bolesti, kombinacije oralnih antidijabetika.
English: • feeling thirsty
Croatian: ● osjećaj žeđi ● mučnina
English: Operations and X-rays Tell your doctor you are taking Vokanamet if you are going to have:
Croatian: Recite svom liječniku da uzimate Vokanamet ako ćete biti podvrgnuti:
English: Sitagliptin 100 mg + metformin and sulfonylurea (N=378)
Croatian: Sitagliptin 100mg + metformin i sulfonilureja (N=378)
English: 300 mg, respectively, compared to 2.7% for placebo.
Croatian: 100 mg odnosno 300 mg u usporedbi s 2,7% za placebo.
English: In the pooled analysis of the four 26-week, placebo-controlled studies, the incidence of all adverse reactions related to volume depletion (e.g., postural dizziness, orthostatic hypotension, hypotension, dehydration, and syncope) was 1.2% for canagliflozin 100 mg once daily, 1.3% for canagliflozin 300 mg once daily, and 1.1% for placebo.
Croatian: U analizi udruženih podataka iz četiri 26-tjedna placebom kontrolirana ispitivanja incidencija svih nuspojava povezanih s deplecijom volumena (npr. posturalna omaglica, ortostatska hipotenzija, hipotenzija, dehidracija i sinkopa) bila je 1,2% za kanagliflozin od 100 mg jedanput na dan, 1,3% za kanagliflozin od 300 mg jedanput na dan i 1,1% za placebo.
English: Tablet core: microcrystalline cellulose, hypromellose, croscarmellose sodium, and magnesium stearate.
Croatian: Drugi sastojci su: Jezgra tablete: mikrokristalična celuloza, hipromeloza, umrežena karmelozanatrij i magnezijev stearat.
English: d p = 0.013 compared to placebo.
Croatian: d p=0,013 u usporedbi s placebom.
English: Canagliflozin 100 mg once daily as dual therapy with metformin produced similar reductions in HbA1c from baseline and 300 mg produced superior (p < 0.05) reductions in HbA1c compared to glimepiride, thus demonstrating non-inferiority.
Croatian: 100 mg jedanput na dan kao dvojna terapija s metforminom izazvao je slična smanjenja HbA1c od početne vrijednosti, a 300 mg je izazvao superiorna (p<0,05) smanjenja HbA1c u usporedbi s glimepiridom, te prema tome pokazao neinferiornost.
English: • in patients on their maximally tolerated doses of metformin along with other glucose-lowering medicinal products including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5, and 5.1 for available data on different add-on therapies)
Croatian: ● u bolesnika kod kojih maksimalne podnošljive doze metformina, zajedno s drugim lijekovima koji snižavaju glukozu uključujući inzulin, ne omogućavaju adekvatnu regulaciju glikemije (za dostupne podatke o različitim vrstama dodatnih terapija vidjeti dijelove 4.4, 4.5 i 5.1)
English: In in vitro studies, canagliflozin neither inhibited cytochrome P450 CYP1A2, CYP2A6, CYP2C19, CYP2D6, or CYP2E1, CYP2B6, CYP2C8, CYP2C9, nor induced CYP1A2, CYP2C19, CYP2B6,
Croatian: U in vitro ispitivanjima, pri koncentracijama višim od terapijskih, kanagliflozin niti je inhibirao citokrome P450 CYP1A2,CYP2A6, CYP2C19, CYP2D6, ili CYP2E1, CYP2B6, CYP2C8, CYP2C9,
English: Vokanamet contains two different active substances, canagliflozin and metformin.
Croatian: Što je Vokanamet i za što se koristi Vokanamet sadrži dvije različite djelatne tvari, kanagliflozin i metformin.
English: ● in patients not adequately controlled on their maximally tolerated doses of metformin alone
Croatian: Za bolesnike koji nisu adekvatno regulirani uz maksimalne podnošljive doze metformina
English: b p < 0.001 compared to placebo.
Croatian: b p<0,001 u usporedbi s placebom.
English: Mean percent increases from baseline for canagliflozin 100 mg and 300 mg versus placebo, respectively, were total cholesterol 3.4% and 5.2% versus 0.9%; HDL-cholesterol 9.4% and 10.3% versus 4.0%; LDL-cholesterol 5.7% and 9.3% versus 1.3%; non-HDL-cholesterol 2.2% and 4.4% versus 0.7%; triglycerides 2.4% and 0.0% versus 7.6%.
Croatian: i Srednji postotak porasta u odnosu na početnu vrijednost za kanagliflozin od 100 mg odnosno 300 mg naspram placeba, bio je za ukupni kolesterol 3,4% i 5,2% naspram 0,9%; HDL kolesterol 9,4% i 10,3% naspram 4,0%; LDL kolesterol 5,7% i 9,3% naspram 1,3%; ne HDL kolesterol 2,2% i 4,4% naspram 0,7%; trigliceride 2,4% i 0,0% naspram 7,6%.
English: Nervous system disorders common
Croatian: Poremećaji živčanog sustava često
English: Vokanamet 50 mg/850 mg film-coated tablets Vokanamet 50 mg/1000 mg film-coated tablets Vokanamet 150 mg/850 mg film-coated tablets Vokanamet 150 mg/1000 mg film-coated tablets canagliflozin/metformin hydrochloride
Croatian: Vokanamet 50 mg/850 mg filmom obložene tablete Vokanamet 50 mg/1000 mg filmom obložene tablete Vokanamet 150 mg/850 mg filmom obložene tablete Vokanamet 150 mg/1000 mg filmom obložene tablete kanagliflozin/metforminklorid
English: • The active substances are canagliflozin and metformin hydrochloride.
Croatian: Djelatne tvari su kanagliflozin i metforminklorid.
English: The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.
Croatian: dehidracije, iznenadnog smanjenja doze inzulina ili povećane potrebe za inzulinom zbog velikog kirurškog zahvata ili ozbiljne bolesti.
English: • carbamazepine, phenytoin, or phenobarbital (medicines used to control seizures)
Croatian: ● karbamazepin, fenitoin ili fenobarbital (lijekovi koji se uzimaju za kontrolu napadaja) ● efavirenz ili ritonavir (lijekovi koji se koriste za liječenje HIV infekcije)
English: Canagliflozin
Croatian: KANAGLIFLOZIN
English: CANAGLIFLOZIN
Croatian: Kanagliflozin
English: Compared to sitagliptin as triple therapy with metformin and sulphonylurea (52 weeks) Canagliflozin 300 mg + metformin and sulphonylurea (N=377)
Croatian: N/Pc Usporedba s sitagliptinom kao trojnom terapijom s metforminom i sulfonilurejom (52 tjedna) Kanagliflozin 300 mg + metformin i sulfonilureja (N=377)
English: ● Moderate and severe renal impairment (patients with eGFR < 60 mL/min/1.73 m2 or
Croatian: Umjereno i teško oštećenje bubrežne funkcije (bolesnici s eGFR < 60 mL/min/1,73 m2 ili
English: Due to its mechanism of action, canagliflozin, by increasing urinary glucose excretion (UGE), induces an osmotic diuresis, which may reduce intravascular volume and decrease blood pressure (see section 5.1).
Croatian: inducira osmotsku diurezu, što može reducirati intravaskularni volumen i smanjiti krvni tlak (vidjeti dio 5.1).
English: compared to 0.0% for placebo.
Croatian: 300 mg u usporedbi s 0,0% za placebo.
English: Table 2: The frequency of metformin adverse reactions identified from clinical trial and postmarketing data
Croatian: Tablica 2: Učestalost nuspojava metformina koje su identificirane u kliničkim ispitivanjima i u razdoblju nakon stavljanja lijeka u promet
English: This is because you are at an increased risk of getting a build-up of lactic acid in your blood (lactic acidosis) if you have too much alcohol.
Croatian: To je zbog toga što Vam je povećan rizik za povišenje koncentracije mliječne kiseline u krvi
English: 1 x 20 film-coated tablets 1 x 60 film-coated tablets 180 (3 x 60) film-coated tablets.
Croatian: 180 (3 x 60) filmom obloženih tableta.
English: • a significant reduction of the absolute risk of any diabetesrelated complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p = 0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p = 0.0034
Croatian: ● značajna redukcija apsolutnog rizika za pojavu bilo koje komplikacije povezane s dijabetesom u skupini s metforminom (29,8 događaja/1000 bolesnik-godini) u odnosu na samu dijetu (43,3 događaja/1000 bolesnik-godini), p=0,0023, te u odnosu na skupinu s kombinacijom sulfonilureje i inzulinom u monoterapiji (40,1 događaja/1000 bolesnik-godini), p=0,0034
English: • vaginal yeast infection.
Croatian: Vrlo često ● vaginalna gljivična infekcija.
English: Using a mixed-meal challenge, canagliflozin as monotherapy or add-on therapy with one or two oral glucose-lowering medicinal products reduced postprandial glucose from baseline relative to placebo by -1.5 mmol/L to -2.7 mmol/L for canagliflozin 100 mg once daily and -2.1 mmol/L to -3.5 mmol/L for canagliflozin 300 mg once daily, respectively, due to reductions in the pre-meal glucose concentration and reduced postprandial glucose excursions.
Croatian: Postprandijalna glukoza Uz mještoviti obrok kao poticaj, kanagliflozin kao monoterapija ili dodatna terapija s jednim ili dva oralna lijeka koji snižavaju glukozu, je smanjio postprandijalnu glukozu (PPG) od početne vrijednosti u odnosu na placebo za -1,5 mmol/L do -2,7 mmol/L za kanagliflozin od 100 mg jedanput na dan odnosno -2.1 mmol/L do -3.5 mmol/L za kanagliflozin od 300 mg jedanput na dan, zbog smanjenja koncentracija glukoze prije jela i smanjena ekskurzije postprandijalne glukoze.
English: Placebo + metformin and sulphonylurea (N = 156)
Croatian: Placebo + metformin i sulfonilureja (N=156)
English: In four placebo-controlled studies, treatment with canagliflozin as monotherapy or add-on therapy with one or two oral glucose-lowering medicinal products resulted in mean changes from baseline relative to placebo in FPG of -1.2 mmol/L to -1.9 mmol/L for canagliflozin 100 mg once daily and -1.9 mmol/L to -2.4 mmol/L for canagliflozin 300 mg once daily, respectively.
Croatian: U četiri placebom-kontrolirana ispitivanja, liječenje kanagliflozinom kao monoterapijom ili dodatnom terapijom s jednim ili dva oralna lijeka koji snižavaju glukozu rezultiralo je promjenom srednje vrijednosti FPG od početne vrijednosti u odnosu na placebo, od -1,2 mmol/L do -1,9 mmol/L za kanagliflozin od 100 mg jedanput na dan odnosno -1.9 mmol/L do -2.4 mmol/L za kanagliflozin od
English: • if you have diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss, feeling sick [nausea], or being sick [vomiting])
Croatian: ● ako imate dijabetičku ketoacidozu (komplikacija šećerne bolesti s visokim šećerom u krvi,
English: Patients (%) achieving HbA1c < 7% Body weight
Croatian: Bolesnici (%) koji su postigli HbA1c < 7% Tjelesna težina
English: Rare cases of diabetic ketoacidosis (DKA), including life-threatening cases, have been reported in clinical trials and post-marketing in patients treated with SGLT2 inhibitors, including canagliflozin.
Croatian: Tijekom kliničkih ispitivanja i nakon stavljanja lijeka u promet, u bolesnika liječenih SGLT2 inhibitorima, uključujući kanagliflozin, prijavljeni su rijetki slučajevi dijabetičke ketoacidoze (DKA), uključujući i slučajeve opasne po život.
English: Mean percent changes from baseline in blood urea nitrogen were 17.1% and 18.0% for canagliflozin 100 mg and 300 mg, respectively, compared to 2.7% for placebo.
Croatian: Srednje vrijednosti postotka promjene urea nitrata u krvi u odnosu na početnu bila je 17,1% i 18,0% za kanagliflozin od 100 mg odnosno 300 mg u usporedbi s 2,7% za placebo.
English: Patients (%) achieving HbA1c < 7% 53.6 Body weight
Croatian: Bolesnici (%) koji su postigli HbA1c < 7% 53,6 Tjelesna težina
English: • in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation
Croatian: ● snižavajući stvaranje glukoze u jetri inhibirajući glukoneogenezu i glikogenolizu ● u mišiću, povećavajući osjetljivost na inzulin, poboljšavajući periferno preuzimanje i iskorištenost glukoze
English: The intravascular administration of iodinated contrast agents in radiologic studies can lead to renal failure.
Croatian: Intravaskularna primjena jodnih kontrastnih sredstava u radiološkim ispitivanjima može uzrokovati zatajenje bubrega.
English: For patients with a baseline eGFR 30 mL/min/1.73 m2 to < 60 mL/min/1.73 m2 or CrCl 30 to < 60 mL/min, the incidences were 4.8% on canagliflozin 100 mg once daily and 8.1% on canagliflozin 300 mg once daily compared to 2.6% in the control group.
Croatian: Za bolesnike s početnom vrijednosti eGFR 30 mL/min/1,73 m2 do < 60 mL/min/1,73 m2 ili CrCl 30 do < 60 mL/min, incidencije su bile 4,8% uz kanagliflozin od
English: To assess risk factors for these adverse reactions, a larger pooled analysis (N=9,439) of patients from eight controlled phase 3 studies including both doses of canagliflozin was conducted.
Croatian: (N=9439) bolesnika iz osam kontroliranih ispitivanja faze 3 uključujući obje doze kanagliflozina.
English: N/Ac a Intent-to-treat population using last observation in study prior to glycaemic rescue therapy.
Croatian: N/Pc a „Intent to treat“ populacija (planirana za liječenje) koristeći posljednje zapažanje u ispitivanju prije hitnog liječenja glikemije drugim lijekovima. b p<0,05.
English: • urinary tract infections
Croatian: ● infekcije mokraćnog sustava
English: Vokanamet must not be used in patients with moderate or severe renal impairment (eGFR < 60 mL/min/1.73m2 or CrCl < 60 mL/min) due to the active substance metformin (see sections 4.3, 4.4 and 5.2).
Croatian: (eGFR < 60 mL/min/1,73m2 ili CrCl < 60 mL/min) zbog djelatne tvari metformina (vidjeti dijelove 4.3, 4.4 i 5.2).
English: • rash or redness of the penis or foreskin (yeast infection)
Croatian: ● osip ili crvenilo muškog spolnog uda ili kožice (gljivična infekcija)
English: • corticosteroids (used to treat a variety of conditions, such as severe inﬂammation of the skin or in asthma) that are given by mouth, as an injection, or inhaled • beta-2 agonists (such as salbutamol or terbutaline) used to treat asthma.
Croatian: ● kortikosteroide (koriste se za liječenje različitih stanja, poput teških upala kože ili astme) koji se uzimaju kroz usta, putem injekcije ili se udišu
English: • Vokanamet 150 mg/1000 mg film-coated tablets (tablets) are purple, capsule-shaped, 22 mm in length, and debossed with “CM” on one side and “611” on the other side.
Croatian: Vokanamet 150 mg/1000 mg filmom obložene tablete (tablete) su ljubičaste boje, oblika kapsule, duljine 22 mm, s utisnutim “CM” na jednoj strani i “611” na drugoj strani.
English: ● Acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock;
Croatian: Akutna ili kronična bolest koja može izazvati hipoksiju tkiva kao što je: srčano ili respiratorno zatajenje, nedavni infarkt miokarda, šok; ● Oštećenje jetrene funkcije, akutno trovanje alkoholom, alkoholizam (vidjeti dijelove 4.2 i 4.5).
English: Patients (%) achieving HbA1c < 7% 19.8b
Croatian: Bolesnici (%) koji su postigli HbA1c < 7% 19,8 b
English: 9.3% versus 1.3%; non-HDL-cholesterol 2.2% and 4.4% versus 0.7%; triglycerides 2.4% and 0.0% versus 7.6%.
Croatian: bio je za ukupni kolesterol 3,4% i 5,2% naspram 0,9%; HDL kolesterol 9,4% i 10,3% naspram 4,0%; LDL kolesterol 5,7% i 9,3% naspram 1,3%; ne HDL kolesterol 2,2% i 4,4% naspram 0,7%; trigliceride 2,4% i 0,0% naspram 7,6%.
English: • Vokanamet 50 mg/850 mg film-coated tablets (tablets) are pink, capsule-shaped, 20 mm in length, and debossed with “CM” on one side and “358” on the other side.
Croatian: Vokanamet 50 mg/850 mg filmom obložene tablete (tablete) su ružičaste boje, oblika kapsule, duljine 20 mm, s utisnutim “CM” na jednoj strani i“358” na drugoj strani.
English: • Vokanamet 50 mg/1000 mg film-coated tablets (tablets) are beige, capsule-shaped, 21 mm in length, and debossed with “CM” on one side and “551” on the other side.
Croatian: Vokanamet 50 mg/1000 mg filmom obložene tablete (tablete) su bež boje, oblika kapsule, duljine 21 mm, s utisnutim “CM” na jednoj strani i “551” na drugoj strani.
English: 150 mg twice daily (N = 93)
Croatian: 150 mg dva puta na dan (N=93)
English: 50 mg twice daily (N = 93)
Croatian: 50 mg dva puta na dan (N=93)
English: The tablet is pink, capsule-shaped, 20 mm in length, immediate-release, film-coated, and debossed with “CM” on one side and “358” on the other side.
Croatian: Tableta je ružičaste boje, oblika kapsule, duljine 20 mm, s trenutnim oslobađanjem, filmom obložena, s “CM” utisnutim s jedne strane i “358” s druge strane.
English: How to store Vokanamet
Croatian: Moguće nuspojave Kako čuvati Vokanamet
English: l Mean percent changes from baseline in blood urea nitrogen were 17.1% and 18.0% for canagliflozin 100 mg and
Croatian: l Srednje vrijednosti postotka promjene urea nitrata u krvi u odnosu na početnu bila je 17,1% i 18,0% za kanagliflozin od
English: • Vokanamet 150 mg/850 mg film-coated tablets (tablets) are light yellow, capsule-shaped, 21 mm in length, and debossed with “CM” on one side and “418” on the other side.
Croatian: Vokanamet 150 mg/850 mg filmom obložene tablete (tablete) su svijetložute boje, oblika kapsule, duljine 21 mm, s utisnutim “CM” na jednoj strani i “418” na drugoj strani.
English: Patients (%) achieving HbA1c < 7% 45.5b
Croatian: Bolesnici (%) koji su postigli HbA1c < 7% 45,5 b
English: Patients (%) achieving HbA1c < 7% 47.8d
Croatian: Bolesnici (%) koji su postigli HbA1c < 7% 47,8d